2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile
• 英文别名: 2-[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)sulfanylmethyl]benzonitrile
• 化学式: C₁₄H₉BrN₄S
• 分子量: 345.22
• InChiKey: DEYMHFHACXKPOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  90.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH)<br/>[FR] MÉTHODES DE RAJEUNISSEMENT DE TISSUS ÂGÉS PAR L'INHIBITION DE LA 15-HYDROXYPROSTAGLANDINE DÉSHYDROGÉNASE (15-PGDH)
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2020252146A1

  公开（公告）日：2020-12-17

  The present disclosure provides compositions and methods based on the identification of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a therapeutic target in aging, dystrophic muscle to improve muscle atrophy, increase muscle mass, function and strength. Further provided herein are compositions and methods for the rejuvenation of aged tissue. In particular, 15-PGDH inhibitors, such as SW033291, are used to elevate the levels of prostaglandin E2 (PGE2) in the muscle or tissue.

  本公开提供了基于将15-羟基前列腺素脱氢酶（15-PGDH）识别为老化、营养不良肌肉中的治疗靶点的组合物和方法，以改善肌肉萎缩，增加肌肉质量、功能和力量。此外，还提供了用于恢复老化组织的组合物和方法。具体而言，使用15-PGDH抑制剂，如SW033291，来提高肌肉或组织中前列腺素E2（PGE2）的水平。
• METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH)
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：EP3982957A1

  公开（公告）日：2022-04-20
• [EN] ELEVATION OF MITOCHONDRIAL BIOGENESIS AND FUNCTION BY INHIBITION OF PROSTAGLANDIN DEGRADING ENZYME 15-PGDH<br/>[FR] ÉLÉVATION DE LA BIOGENÈSE ET DE LA FONCTION MITOCHONDRIALES PAR INHIBITION DE L'ENZYME DE DÉGRADATION DES PROSTAGLANDINES 15-PGDH
  申请人：[en]THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

  公开号：WO2022087631A1

  公开（公告）日：2022-04-28

  The present disclosure provides methods of increasing mitochondrial biogenesis, function, or both in a tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating diseases, disorders, or conditions associated with dysfunctional mitochondria and/or increased oxidative stress including mitochondrial diseases.